GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response

GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response

Copyright © 2010 Elsevier Inc. All rights reserved.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 137(2010), 1 vom: 15. Okt., Seite 31-40
Auteur principal: Chéramy, Mikael (Auteur)
Autres auteurs: Skoglund, Camilla, Johansson, Ingela, Ludvigsson, Johnny, Hampe, Christiane S, Casas, Rosaura
Format: Article en ligne
Langue:English
Publié: 2010
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Adjuvants, Immunologic Alum Compounds Antibodies Autoantibodies C-Peptide ICA512 autoantibody Immune Sera plus... Immunoglobulin G Tetanus Toxoid aluminum sulfate 34S289N54E Immunoglobulin E 37341-29-0 Glutamate Decarboxylase EC 4.1.1.15 glutamate decarboxylase 2
Accès en ligne Volltext